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ALCIUM channel antagonists are a recently developed group of vasodilators that inhibit the influx of calcium through receptor-or voltageoperated ion channels in cell membranes. 8, 12, 23 Initially, the clinical use of these drugs was limited to the treatment of cardiovascular disorders such as vasospastic angina, arrhythmias, and hypertension) -~ Recently, however, a role for calcium antagonists has also been proposed in the treatment of the cerebral arterial spasm that often follows a subarachnoid hemorrhage (SAH). 2"3'1~176 In recently completed clinical trials, the calcium antagonist, nimodipine, was found effective in preventing symptomatic vasospasm following SAH. 1. 4 Radioligand studies have been used to characterize the binding sites labeled by 3H-calcium antagonists in a number of tissues and species? -7-~ 1, 13,14.16-18.24 Indeed, three distinct classes of calcium antagonists have been described in non-human tissues on the basis of radioligand studies. ~3, 17 The presence of calcium antagonist receptor sites in human tissues, however, has not yet been documented. In the present report, we describe the specific and saturable binding of 3H-nimodipine in human brain membranes. The pharmacological characteristics of this site suggest an association with calcium channels in human brain tissue.
Materials and Methods
Human frontal cortex was obtained at autopsy within 12 hours of death. Cortical samples were dissected free of meninges, frozen over dry ice, and stored at -70~ until used in assays within the next 3 weeks. On the day of experimental use, a 1-to 2-gm sample of tissue was placed at room temperature for 1 hour and suspended in 50 vol of 50 mM Tris-HC1 buffer (pH 7.7 at 25~ using a Tekmar polytron for 10 seconds. The tissue suspension was then centrifuged at 50,000 G for 10 minutes, resuspended in 50 vol of Tris-HC1 buffer, and again centrifuged at 50,000 G for 10 minutes. The pellet was again suspended in 80 vol of the standard assay buffer which included 50 mM Tris-HC1, 4 mM CaCI,, and 0.1% ascorbic acid. Final tissue concentration was 10 mg wet weight/ml. Tissue used in the calcium regulation studies was initially suspended in 50 mM Tris-HC1 and 5 mM ethylenediaminetetraacetic acid (EDTA) at 37~ for 5 minutes prior to the standard tissue preparation described above.
Incubation tubes received 100 ul of-~H-nimodipine, 100 ~1 of various drugs, and 0,8 ml of tissue suspension during standard assays. All assays were performed in triplicate. The concentration of 3H-nimodipine in drug displacement studies was 0.1 riM. The tubes were incubated at 25~ for 1 hour and then the contents rapidly filtered under vaccum through Whatman GF/B filters with three 5-ml washes of ice-cold 50 mM Tris-HC1 buffer. The filters were counted by liquid scintillation spectrometry in 10 ml of Ultraflor at efficiencies of 40% to 44%.
Specific binding of 3H-nimodipine was defined as the excess over blank value obtained in the presence of 100 nM nifedipine. In drug displacement studies using 0.1 nM 3H-nimodipine, approximately 70% to 80% of the binding was specific. 3H-nimodipine (160 Ci/mmole) was dissolved in standard assay buffer immediately before use. Drugs were dissolved in assay buffer or ethanol at 10-3M concentrations and appropriately diluted in standard assay buffer.*
Results

3H-Nimodipine Binding to Human Brain
The binding of 3H-nimodipine to human brain membranes is saturable (Fig. 1A) . Specific binding accounts for approximately 70% to 80% &total binding at concentrations below 0.1 nM 3H-nimodipine, the amount of 3H-ligand used in routine drug displacement studies. At concentrations above 0.1 nM, specific binding represents a decreasing percentage of total binding, and is only 45% of total binding at 1.0 nM 3H-nimodipine. The apparent monophasic saturation curve for 3H-nimodipine is confirmed by Scatchard analysis shown in 
Regulation of 3H-Nimodipine Binding by Calcium Chloride
Human frontal cortex binding of 3H-nimodipine is dependent on calcium (Fig. 2) , a property shared with 3H-calcium antagonist binding sites in non-human tissues.Z3'~4 After pretreatment with EDTA, specific binding of 3H-nimodipine is reduced to 24% of control values taken under standard assay conditions (that is, in the presence of 4 mM CaC12). The addition of 10-6M CaCI2 causes a slight increase in specific binding, with maximal stimulation of 3H-nimodipine binding occurring at 1 mM CaC12. Specific binding is essentially stable at between I and 100 mM of calcium. Half-maximal stimulation is obtained at approximately 3 x 10-SM CaCI2. Pretreatment with EDTA had no effect on nonspecific binding (data not shown).
Drug Effects of ~H-Nimodipine Binding to Human Brain
Nimodipine, nitrendipine, and nifedipine are all potent inhibitors of 3H-nimodipine binding (Fig. 3) In marked contrast, the interactions ofverapamil and diltiazem with 3H-nimodipine binding are extremely complex. Diltiazem has no effect on the binding of3H o nimodipine until it reaches a concentration of approximately 10-7M, when it increases the specific binding of the 3H-ligand. The increase in binding reaches a maximum of 140% between 3 x 10-6M and 10-SM diltiazem. The specific binding of 3H-nimodipine then decreases rapidly above 3 x 10-SM diltiazem. Verapamil, on the other hand, displaces 3H-nimodipine at concentrations above 10-SM. However, the inhibitory effect of verapamil plateaus between 3 x 10-7M and 10-5M. No further displacement is noted until concentrations above 3 x 10-SM verapamil are obtained.
The apparent affinity constants (K~) for a variety of calcium channel antagonists are given in Table 1 . The 1,4-dihydropyridines, as well as sodium nitroprusside, display monophasic inhibition of ~H-nimodipine. This type of inhibition suggests that these drugs are competitive antagonists at the 3H-ligand binding site. Nimodipine and nitrendipine are essentially equipotent while nifedipine is approximately three times weaker in displacing 3H-nimodipine. Sodium nitroprusside does displace 3H-nimodipine but only at comparatively high concentrations. Propranolol, which has no known calcium antagonist properties, ~9 is inactive in displacing 3H-nimodipine at concentrations to 10-SM.
Because of the atypical displacement curves of diltiazem and verapamil, apparent K~ values cannot be determined. However, assuming the "plateau" in 3H-nimodipine binding represents a maximal pharmaco- 260 _+ 100 * EDso values were determined by using 0.1 nM 3H-nimodipine in the presence or absence of three to 11 concentrations of each drug under standard assay conditions. EDso values were determined by logprobit analysis and apparent K~ values were calculated from the equation Ki = EDso/(I + 3H-nimodipine/Ko). The KD of 3H-nimodipine (0.27 nM) was obtained from Fig. 1 . Values given are the means _+ standard errors of four experiments, each performed in triplicate. logical action, concentrations were determined which would produce 50% of this effect (EDso). As shown in Table 1 , both verapamil (250 nM) and diltiazem (260 nM) are equipotent in terms of causing a shift in the binding parameters of 3H-nimodipine. As noted in Fig.  3 , however, their pharmacological effects have opposite results on the specific binding of 3H-nimodipine; verapamil decreases the binding while diltiazem increases the specific binding of 3H-nimodipine.
Discussion
The major finding of the present study is that the calcium antagonist, 3H-nimodipine, labels a high-affin-ity saturable binding site in human frontal cerebral cortex. The binding site is also regulated by calcium with a maximal number of sites labeled in the presence of 1 to 100 mM calcium. Drug competition studies reveal monophasic inhibition by the 1,4-dihydropyridines but complex interactions with other calcium antagonists. These studies represent the first identification of 3H-calcium antagonist binding sites in human brain, and confirm and extend recent reports of specific calcium channel antagonist binding sites in non-human tissues. Thus, "calcium antagonist" drugs differ with respect to both potency and molecular site of action.
Binding studies in non-human tissues have been used to describe three classes of calcium channel antagonists, j3'17 Class I agents are represented by the 1,4-dihydropyridines and display monophasic inhibition of 3H-ligand binding. The apparent Ki of nimodipine and nifedipine also correlates with drug inhibition of certain physiological responses such as agonist-induced contractions of rabbit 2~ and canine basilar arteries. 3 Class II agents include verapamil and methoxyverapamil (D600); these decrease the binding of 3H-calcium antagonists. Class III drugs, of which diltiazem is the prototype, increase 3H-ligand binding to calcium antagonist receptors, j3'17 Thus, 3H-nimodipine binding in human brain also allows for the differentiation of three distinct classes of calcium antagonists.
Calcium channel antagonists have unique and selective effects on intracerebral vasculature and appear to be beneficial in the treatment of delayed ischemic neurological deficits from cerebral arterial spasm. ~' 4 During clipping of a ruptured aneurysm, topically applied nimodipine was found to cause vasodilatation. 4 The observed dilatatory effect was most marked in small vessels. In the recently completed controlled trial, 1 nimodipine given orally was found to significantly prevent the occurrence of severe neurological deficits from spasm. Nimodipine did not, however, completely prevent the occurrence of neurological symptoms from spasm. Random cerebrospinal fluid levels of nimodipine were obtained from six patients in the study and averaged 1.8 nM. Assuming that the nimodipine binding site in the human cerebral arteries is identical to that of human frontal cortex with KD value of 0.27 nM, a concentration of 1.8 nM nimodipine should occupy 80% to 90% of the receptors under ideal conditions. In reality, the in vivo effective concentration of nimodipine for its physiological receptor site is probably somewhat higher due to tissue distribution, protein binding, and drug interaction with other competitors for the calcium channel recognition site. This point is illustrated by the EDs0 of 1.4 nM for nimodipine calculated by log-probit analysis of 50 nM serotonin-induced contractions of canine basilar artery segments in vitro. 9 In the intact animal or human, the EDs0 is probably even greater.
In conclusion, high-affinity saturable 3H-nimodipine binding can be obtained in human brain membranes.
The pharmacological characteristics of this recognition site suggest the direct labeling of the calcium channel antagonist receptor. The complex nature of the binding parameters confirms and extends studies in non-human tissues. Radioligand binding studies are a rapid and sensitive method that can be used in the pharmacological analysis of calcium channel antagonists. The results obtained by these in vitro studies should provide a useful guide for the selection of drugs and dosages in future clinical trials of calcium channel antagonists.
